CLOs on the Move

Aruvant

www.aruvant.com

 
Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aruvant.com
  • 151 West 42nd Street, 15th Floor
    New York, NY USA 10036
  • Phone: 646.495.5310

Executives

Name Title Contact Details
Moya Daniels
 Senior Vice President of Regulatory Affairs and Quality Assurance Profile

Similar Companies

PreciThera

PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.

MB Research Laboratories

MB Research Laboratories is a Spinnerstown, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Oncocyte

Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.

Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Enzyvant

Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.